Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only
Completed
GlaxoSmithKline
Phase 2
2007-04-01
This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are
either taking no diabetes medication or who are taking metformin only. This study will
investigate the safety, tolerability, and efficacy of Albiglutide (GSK716155) and will
measure the levels of Albiglutide (GSK716155) in the bloodstream when it is given for 16
weeks. As a comparison, some subjects will receive exenatide instead of Albiglutide
(GSK716155). The study will involve weekly visits for 17 weeks,and less frequent follow-up
visits for an additional 10 weeks. Assessments include repeat blood sampling and monitoring
of any side effects.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
